CoapTech

Executive Summary

CoapTech is a Baltimore-based medical device company that has developed the PUMA-G System, the first FDA-cleared ultrasound-based solution for bedside gastrostomy (feeding tube) placement. By eliminating the need for endoscopy, fluoroscopy, or an operating room, the technology significantly reduces procedure time, cost, and risk, enabling faster patient recovery and broader access to care. The company targets a large addressable market—over 200,000 gastrostomy procedures annually in the US alone—and is positioned to disrupt traditional methods that require expensive equipment and specialist intervention. With a strong intellectual property portfolio and a focus on improving patient outcomes, CoapTech is poised for commercial growth, though it faces competition from established endoscopic and surgical approaches. Recent partnerships and positive clinical feedback support adoption, but scalability and reimbursement remain key challenges. The company's innovative approach and regulatory momentum make it an interesting investment opportunity in the medical device space.

Upcoming Catalysts (preview)

• Q3 2026Commercial expansion into new hospital systems through value-analysis committee approvals60% success
• Q4 2026Publication of additional clinical data demonstrating cost savings and improved patient outcomes75% success
• Q2 2027FDA clearance for pediatric or other expanded indications50% success